Literature DB >> 16815259

Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

Russell W Read1, Fei Yu, Massimo Accorinti, Bahram Bodaghi, Soon-Phaik Chee, Christine Fardeau, Hiroshi Goto, Gary N Holland, Hidetoshi Kawashima, Eri Kojima, Phuc Lehoang, Claire Lemaitre, Annabelle A Okada, Paola Pivetti-Pezzi, Antonio Secchi, Robert F See, Khalid F Tabbara, Masahiko Usui, Narsing A Rao.   

Abstract

PURPOSE: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
DESIGN: Retrospective comparative interventional case series. SETTINGS: Nine international uveitis specialty clinics. STUDY POPULATION: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. INTERVENTION: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). MAIN OUTCOME MEASURES: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy.
RESULTS: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period.
CONCLUSIONS: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815259     DOI: 10.1016/j.ajo.2006.02.049

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  30 in total

1.  A challenging case of tuberculosis-associated uveitis after corticosteroid treatment for Vogt-Koyanagi-Harada disease.

Authors:  Tian-Wei Qian; Su-Qin Yu; Xun Xu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

2.  [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].

Authors:  K Wand; S Abraham; D Loos; S Stumpfe; C Lohmann; M Maier; N Feucht
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

Review 3.  Uveitis: advances in understanding of pathogenesis and treatment.

Authors:  Russell W Read
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

4.  Late onset acute Vogt-Koyanagi-Harada syndrome-challenges on the way.

Authors:  Sandra Rodrigues-Barros; Jacqueline Martins Sousa; Bruno Carvalho; Gabriel Andrade; Heloísa Nascimento
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

5.  Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.

Authors:  Pascal B Knecht; Alessandro Mantovani; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2013-01-01       Impact factor: 2.031

6.  Headache as an initial manifestation of Vogt-Koyanagi-Harada disease.

Authors:  Abdulrahman Samir Khairallah
Journal:  Saudi J Ophthalmol       Date:  2013-10-14

7.  The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.

Authors:  Un Chul Park; In Hwan Cho; Eun Kyung Lee; Hyeong Gon Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-05       Impact factor: 3.117

8.  Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings.

Authors:  Daniel V Vasconcelos-Santos; Elliott H Sohn; Srinivas Sadda; Narsing A Rao
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

9.  Management of ocular complications of Vogt-Koyanagi-Harada syndrome.

Authors:  Irfan Perente; Canan Asli Utine; Hanefi Cakir; Vedat Kaya; Ilknur Tugal Tutkun; Omer Faruk Yilmaz
Journal:  Int Ophthalmol       Date:  2007-10-19       Impact factor: 2.031

10.  Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.

Authors:  Elizabeth Shen; Sivakumar R Rathinam; Manohar Babu; Anuradha Kanakath; Radhika Thundikandy; Salena M Lee; Erica N Browne; Travis C Porco; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2016-06-10       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.